

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy

Rick Proschmann,¹ Christoph Baldow,¹ Timo Rothe,¹ Meinolf Suttrop,² Christian Thiede,³ Josephine T. Tauer,² Martin C. Müller,⁴ Andreas Hochhaus,⁵ Ingo Roeder^{1,6} and Ingmar Glauche¹

¹Faculty of Medicine Carl Gustav Carus, Institute for Medical Informatics and Biometry, Technische Universität Dresden; ²Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", Technische Universität Dresden; ³Department of Internal Medicine, Medical Clinic I, University Hospital "Carl Gustav Carus", Technische Universität Dresden; ⁴Department of Internal Medicine, Medical Clinic III, Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim; ⁵Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena and ⁶National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany


*Correspondence: ingmar.glauche@tu-dresden.de
doi:10.3324/haematol.2016.154138*

Supplementary Figures



Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy

Rick PROSCHMANN, Christoph BALDOW, Tino ROTHE, Meinolf SUTTORP, Christian THIEDE, Josephine T. TAUER, Martin C. MÜLLER, Andreas HOCHHAUS, Ingo ROEDER, Ingmar GLAUCHE


Supplementary figure 1: 25 out of 40 patients with biphasic decline kinetics, sufficient treatment data and follow-up, used for statistical analysis.




Supplementary figure 2: 2 Patients excluded due to low number of measurements (<7).



Supplementary figure 3: 4 Patients excluded due to insufficient treatment follow-up (<12 months). Note that patient with ID 13 is also excluded due to insufficient number of samples.



Supplementary figure 4: 14 patients with uniphasic decline kinetics, excluded from statistical analysis. Patients 7, 13, 67, 85 are also excluded due to insufficient follow up or low number of measurements available.



Note: corresponding time courses for the adult reference cohort are available as Supplementary Material to the following article:

I. Roeder, M. Horn, I. Glauche, A. Hochhaus, M. C. Mueller, M. Loeffler (2006):
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.
 Nature Medicine 12(10): 1181 - 1184